Prime Medicine (PRME) 10-Q2024 Q1 Quarterly report

Filed: 10 May 24, 8:22am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adult, agent, AgreementSM, anytime, ATM, caption, chronic, core, Cystic, Distinguishing, envision, equal, Hedging, hematology, holder, implied, Jeffrey, linkedin, LLC, lung, Marrazzo, multinational, mutual, nomination, ocular, partnership, pediatric, primemedicine, pro, rata, settle, shelf, Twitter, warrant

Removed: accommodate, addressing, adjusted, adjustment, Aimed, amendment, blue, broadest, broadly, category, cell, chosen, chromosome, conception, consultant, continued, conversion, converted, correct, create, created, deferred, Deliberately, deliver, directly, DNA, ear, edit, effected, Erie, eye, facility, fastest, final, focusing, full, hematopoietic, indirectly, initially, innovative, invest, lab, MEF, obligated, offer, overarching, overlap, path, pathological, proportional, purposefully, push, rare, redeemable, remain, rental, repair, repeat, retroactively, reverse, secure, seek, sky, split, stem, Street, technical, terminate, theoretical, treat, ultimately

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PRME similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report of Prime Medicine, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 10, 2024
	By:	/s/ Allan Reine
		Allan Reine
		Chief Financial Officer
		(Principal Financial Officer)